123: Previewing Cleveland Clinic's Epilepsy Summit
122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate
115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis
120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
118: Gaining Patient Perspectives on Impact of Narcolepsy
117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development
Special Episode: FDA Approval of Diazepam Buccal Film for Pediatric Seizures
113: Lessons Learned in Alzheimer Drug Development
112: Exploring Dimethyl Fumarate to Treat Friedreich Ataxia
Special Episode: FDA Approval of Givinostat for Duchenne Muscular Dystrophy
111: Reviewing ACTRIMS 2024
110: Differential Diagnosis of Sleep Disorders and Hypersomnias
109: AB126, Exosomes, and Cerebroprotection for Stroke
108: Advancing the Genetic Pool of Parkinson Disease
107: Revealing Mechanisms of Sudden Unexplained Death in Toddlers
106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis
105: Recapping Conversations in Neurology From 2023
104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2
103: Advancing Epilepsy Care and Seizure Localization in Pediatrics
102: Potential of Gamma Sensory Stimulation in Alzheimer Disease
Special Episode: FDA Greenlights Vamorolone for Duchenne Muscular Dystrophy
101: Ways to Enhance Neuromodulation in Parkinsonism
Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis
100: 2023 ECTRIMS-ACTRIMS Meeting Highlights
99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy
98: Uncovering Phenotypical Features of Narcolepsy Type 1
97: Identifying Gaps in Access to Parkinson Disease Care
96: Complexities With Cognitive Screening in Primary Care Settings
Special Episode: Addition of Valbenazine to Treat Huntington Disease Chorea
95: Expanding Potential for Long-Term Treatment in SMA
94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease
93: Caring for Women With Parkinson Disease
92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings
Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy
91: Assessing the Landscape of Sleep Disorder Care
90: Raising Stroke Awareness and Improving Clinical Care
89: Potential of CNM-Au8 Gold Nanocrystals to Treat ALS
88: 2023 AAN Annual Meeting Highlights
Special Episode: Tofersen Approved for SOD1 ALS
87: Severe Multiple Sclerosis and the CASA-MS Study
86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis
85: Impact of Narcolepsy on Social Relationship Health in Adolescents
Special Episode: Trofinetide Approved for Rett Syndrome
84: Parkinson Disease Education for Community Providers
83: The ARISE Study and Using DMTs in RIS
next page